A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

Trial Profile

A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 09 Dec 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.(NCT00958334)
    • 09 Dec 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.(NCT00958334)
    • 09 Dec 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.(NCT00958334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top